Since December, the Albany International Airport has been offering covid testing to all travellers and staff at the airport. The test, called the Clarifi COVID-19 Test Kit, was co-developed by Quadrant Biosciences and SUNY Upstate Medical University in Syracuse, and has been used to test over a half million students and faculty at SUNY colleges

This past December, the United States Food and Drug Administration (FDA) ranked the Clarifi COVID-19 Test Kit as the most sensitive COVID-19 saliva test currently available on the market.  In a statement released by the office of Governor Andrew Cuomo, the Governor congratulated Quadrant Biosciences and SUNY Upstate Medical for our work

Quadrant Biosciences and SUNY Upstate Medical University have been chosen as recipients of MedTech’s 2020 Project of the Year award for the development of the Clarifi COVID-19 saliva test. The award recognizes an initiative that has had a “singular and demonstrable positive impact on public health.” The Clarifi COVID-19 saliva test was

Could saliva be the key to concussion diagnosis and management?  Scientists say yes, according to the study “Diagnosing Mild Traumatic Brain Injury Using Saliva RNA Compared to Cognitive and Balance Testing,” published in Clinical and Translational Medicine.

Over the past six months, Quadrant Biosciences has been working in collaboration with New York State to develop and implement several COVID-19 detection projects. These include a program to detect the SARS-CoV-2 RNA virus in wastewater, and a pooled testing program for New York colleges. 

Quadrant Biosciences is excited to share that Dr. Thomas Frazier II, PhD, will be joining our clinical advisory board. Dr Frazier is currently a Professor of Psychology at John Carroll University one of the leading researchers in the field of autism. 

Our company has successfully received a CPT® Proprietary Laboratory Analyses (PLA) Code from the American Medical Association for our autism saliva test, Clarifi ASD. This PLA code officially became effective on April 1, 2020. 

We’re excited to share that our company has been working on a new, rapid diagnostic test for COVID-19.

We’re excited to share a new opportunity for investors looking to help improve the lives of  families across the country.  Quadrant Biosciences is now offering common shares to the general public through the equity crowdfunding platform, Wefunder.